New hope for wet AMD: experimental drugs take on standard treatment in major trial
Disease control
Ongoing
This phase 3 study tests two new drugs (tarcocimab tedromer and tabirafusp tedromer) against a standard treatment (aflibercept) for wet age-related macular degeneration, a leading cause of vision loss. About 675 people with untreated wet AMD will receive one of the three treatmen…
Phase: PHASE3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated May 17, 2026 19:20 UTC